Search Results

You are looking at 21 - 30 of 85 items for :

  • Refine by Access: All content x
Clear All
Open access

Benjamin G Challis, Andrew S Powlson, Ruth T Casey, Carla Pearson, Brian Y Lam, Marcella Ma, Deborah Pitfield, Giles S H Yeo, Edmund Godfrey, Heok K Cheow, V Krishna Chatterjee, Nicholas R Carroll, Ashley Shaw, John R Buscombe, and Helen L Simpson

 = 12); stage IIA ( n  = 5); stage IIB ( n  = 1); stage IIIB ( n  = 3); stage IV ( n  = 3)). Of these, 3 insulinoma (stage IIA ( n  = 2); stage IIIB ( n  = 1)) occurred in the context of MEN-1. We also identified one case of a pro-insulin/GLP-1-secreting

Open access

Signe Frøssing, Malin Nylander, Caroline Kistorp, Sven O Skouby, and Jens Faber

agonists (GLP-1RA) were developed for treatment of hyperglycemia in T2D, but have additionally weight-reducing effect and have proven effective in smaller studies in women with PCOS ( 19 ). The LEADER study in high-risk patients with T2D reported that the

Open access

Kim K B Clemmensen, Jonas S Quist, Dorte Vistisen, Daniel R Witte, Anna Jonsson, Oluf Pedersen, Torben Hansen, Jens J Holst, Torsten Lauritzen, Marit E Jørgensen, Signe Torekov, and Kristine Færch

should be 3.0, not 3.9, the value for Adjusted Estimate of Fasting plasma glucagon should be 0.0 not 0.3, and the value for Unadjusted Estimate of 30 min plasma GLP-1 should be −0.5 not −1.5. These errors do not affect the results or conclusions. The

Open access

Riying Liang, Meijun Wang, Chang Fu, Hua Liang, Hongrong Deng, Ying Tan, Fen Xu, and Mengyin Cai

fibrosis and glomerulosclerosis ( 6 , 7 ). Despite the public health correlation between obesity and kidney injury, there is no effective drug therapy approved for kidney damage. Glucagon-like peptide-1 (GLP-1) is mainly secreted from intestinal L cells

Open access

Annieke C G van Baar, Andrei Prodan, Camilla D Wahlgren, Steen S Poulsen, Filip K Knop, Albert K Groen, Jacques J Bergman, Max Nieuwdorp, and Evgeni Levin

, metabolic syndrome (MetS) and type 2 diabetes ( 1 ). The gut incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), produced by enteroendocrine L cells and K cells, respectively, are intimately involved in

Open access

Marloes Emous, Merel van den Broek, Ragnhild B Wijma, Loek J M de Heide, Gertjan van Dijk, Anke Laskewitz, Erik Totté, Bruce H R Wolffenbuttel, and André P van Beek

). Glucagon-like peptide-1 (GLP-1) is assumed to play a pivotal role in the pathophysiology of PHH, most convincingly because the GLP-1 antagonist exendin (9-39) prevents postprandial hyperinsulinaemia and the subsequent hypoglycaemia in people with severe

Open access

David S Mathiesen, Jonatan I Bagger, Katrine B Hansen, Anders E Junker, Astrid Plamboeck, Signe Harring, Thomas Idorn, Mads Hornum, Jens J Holst, Anna E Jonsson, Torben Hansen, Tina Vilsbøll, Asger Lund, and Filip K Knop

effect is mediated by the two gut hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) ( 6 ). These hormones are secreted from enteroendocrine K and L cells, situated in the intestinal mucosa, in response to

Open access

Metin Guclu, Sinem Kiyici, Zulfiye Gul, and Sinan Cavun

, including insulin, sulfonylureas and thiazolidinediones, cause weight gain instead of weight loss during the management period ( 3 ). Glucagon-like peptide-1 (GLP-1) receptor agonists are used in the treatment of patients with type 2 diabetes mellitus, and

Open access

Marie Reeberg Sass, Nicolai Jacob Wewer Albrechtsen, Jens Pedersen, Kristine Juul Hare, Nis Borbye-Lorenzen, Katalin Kiss, Tina Vilsbøll, Filip Krag Knop, Steen Seier Poulsen, Niklas Rye Jørgensen, Jens Juul Holst, Cathrine Ørskov, and Bolette Hartmann

/Hitachi Modular analytics, Roche Diagnostic) as previously reported ( 7 ). The detection limit for each assay is <2 pmol/L, and intra-assay coefficients of variation are 1.9% (insulin) and 4.6% (C-peptide) ( 8 ). Previously published data on GIP, glucagon, GLP-1

Open access

Malin Nylander, Signe Frøssing, Caroline Kistorp, Jens Faber, and Sven O Skouby

mild degree ( 24 ) and might to some extent diminish the increased thrombin generation induced by oral contraceptives, as recently investigated ( 12 ). Glucagonlike peptide-1 (GLP-1) analogs are commonly used in type 2 diabetes and obesity, where they